Viridian Therapeutics, Inc. (VRDN) Misses Q3 EPS by 9c
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Join SI Premium – FREE
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $91 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Costco (COST) Tops Q4 EPS by 20c
- Northrop Grumman wins three U.S. defense contracts worth $308M
- LPL Financial reports $2.6 trillion in client assets for August 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
